We are live on
!
Find out more
BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$1.11B
1-Year Est. Return
171.34%
This Fund
S&P 500
This Quarter
Est. Return
+1.36%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$895M
AUM Growth
+$57.1M
(+6.8%)
Cap. Flow
+$128M
Cap. Flow
% of AUM
14.27%
Top 10 Holdings %
Top 10 Hldgs %
69.58%
Holding
37
New
4
Increased
8
Reduced
2
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NewAmsterdam Pharma
NAMS
|
+$82.5M |
| 2 |
Natera
NTRA
|
+$57.7M |
| 3 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$20.6M |
| 4 |
Solid Biosciences
SLDB
|
+$17.1M |
| 5 |
X4 Pharmaceuticals
XFOR
|
+$9.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amylyx Pharmaceuticals
AMLX
|
+$28.8M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
+$18.9M |
| 3 |
DVAX
Dynavax Technologies
DVAX
|
+$17.4M |
| 4 |
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
|
+$4.91M |
| 5 |
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
|
+$4.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.35% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xilio Therapeutics
XLO
$59.5M
| $7.55M | 0.84% |
200,387
| – | – |
|
|
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.7M | 0.64% |
1,431,058
| – | – |
|
|
THRD
28
DELISTED
Third Harmonic Bio
THRD
| $4.95M | 0.55% |
1,151,657
-1,128,425
| -49% | -$18.9M |
|
29
Nautilus Biotechnolgy
NAUT
$114M
| $3.6M | 0.4% |
2,000,000
| – | – |
|
30
Invivyd
IVVD
$216M
| $2.91M | 0.32% |
1,937,207
| – | – |
|
|
APTX
31
DELISTED
Aptinyx Inc. Common Stock
APTX
| $2.54M | 0.28% |
8,891,758
| – | – |
|
32
Spyre Therapeutics
SYRE
$9.18B
| $2.41M | 0.27% |
213,908
| – | – |
|
|
33
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
| $86K | 0.01% |
+100,000
| New | +$82.3K |
|
|
34
Amylyx Pharmaceuticals
AMLX
$2.6B
| – | – |
-1,023,214
| Closed | -$28.8M |
|
|
ARYE
35
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| – | – |
-500,000
| Closed | -$4.91M |
|
|
FLACU
36
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| – | – |
-300,000
| Closed | -$3.04M |
|
|
BLSA
37
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| – | – |
-487,500
| Closed | -$4.88M |
|
Similar funds
JTWM
HH
RIM
YL
FLAM
AIM
MTCM
CNC
Bain Capital Life Sciences Investors's Q4 2022 Portfolio in Review
As of Q4 2022, Bain Capital Life Sciences Investors held 37 positions worth $895M, up 6.8% from $838M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Bain Capital Life Sciences Investors deployed $128M of net new capital in Q4 2022, opening 4 new positions and adding to 8 existing holdings. Its largest new stake was NewAmsterdam Pharma: 8,300,000 shares worth $90.5M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Third Harmonic Bio, an estimated $18.9M trimmed.
- Bain Capital Life Sciences Investors's largest Q4 2022 buy was NewAmsterdam Pharma: 8,300,000 shares worth $90.5M.
- Bain Capital Life Sciences Investors added most to Solid Biosciences in Q4 2022, an estimated $17.1M increase.
- Bain Capital Life Sciences Investors's biggest Q4 2022 reduction was Third Harmonic Bio, cutting an estimated $18.9M.
- Bain Capital Life Sciences Investors fully exited Amylyx Pharmaceuticals in Q4 2022, selling an estimated $28.8M.
- Bain Capital Life Sciences Investors's ten largest holdings make up 70% of its $895M portfolio in Q4 2022.
- Bain Capital Life Sciences Investors opened 4 new positions and closed 4 in Q4 2022.
- Bain Capital Life Sciences Investors's portfolio value rose 6.8% quarter-over-quarter to $895M.
Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2022, filed 14 Feb 2023.